Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
about
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary diseaseAcute exacerbation of COPDExacerbations of COPDN-acetylcysteine in COPD: why, how, and when?Positioning new pharmacotherapies for COPDOxidative stress and free radicals in COPD--implications and relevance for treatmentOxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteinePrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Pharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewThe chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implicationsClinical significance of airway mucus hypersecretion in chronic obstructive pulmonary diseaseOxidative Stress in COPD: Sources, Markers, and Potential MechanismsImproved oxidative status in major abdominal surgery patients after N-acetyl cystein supplementationEffect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.COPD: it is time to change!Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter.High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trialPrevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled studyCarbocisteine attenuates TNF-α-induced inflammation in human alveolar epithelial cells in vitro through suppressing NF-κB and ERK1/2 MAPK signaling pathways.The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians.Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.Developing drug therapies in bronchiectasis.Updates in the management of stable chronic obstructive pulmonary disease.Update in Chronic Obstructive Pulmonary Disease 2014.Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis.Maintaining lung health with longstanding HIV.Oxidation pathway and exacerbations in COPD: the role of NAC.Emerging pharmaceutical therapies for COPD.Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.Prediction and prevention of exacerbations and mortality in patients with COPD.Role of Inflammation and Oxidative Stress in the Pathology of Ageing in COPD: Potential Therapeutic Interventions.Bifunctional Drugs for the Treatment of Respiratory Diseases.Optimizing bronchodilation in the prevention of COPD exacerbationsChronic Obstructive Pulmonary Disease Phenotypes: Implications for Care.Multidisciplinary COPD disease management program: impact on clinical outcomes.Increased oxidative stress and depleted antioxidant capacity in chronic obstructive pulmonary disease: Searching for applications.
P2860
Q24186304-EEDBA812-540C-4662-8A51-E5C7975B6176Q26749302-8A8C4DA7-7BC2-49BE-B261-82E82CAD511FQ26764891-19C8EB40-8EA0-45CF-A5EA-9D921F6A0092Q26768289-141B4F3E-10CC-47C8-8100-F9A08A7EB641Q26798659-75E0A620-177C-4D50-BAFB-245EBB050FB6Q26830076-8CE9AB8F-CE34-4BDF-95F6-B6EF1E01B29AQ26864308-651A7A76-CA62-45AF-B753-976D57FDFBF2Q27348844-BD048D7B-914C-4069-B6F7-3A8FCBF1EBA0Q28070274-1AB0CA05-2D5E-4B09-A5B1-2F41D00E56E0Q28081970-6CDCF6C8-63D5-42BE-8870-7F56131EEF7DQ28086971-B08E7466-0756-4EF5-BA6C-606ABEAA3A3BQ29247910-8662289B-8384-4677-B6FF-B423A4AFB402Q35060309-7BCE996C-7AF3-4CEA-B0E9-E6D01D800A48Q35623967-CFFA8B11-1B18-472A-B2E2-8E058614B627Q36288971-B61D42F7-4D61-4C7F-861F-ABE886700122Q36365165-276B34A0-E016-482E-812E-96A671328D65Q36838747-0BD49F47-95B4-474E-8BFF-A6B26D13E271Q36838758-7D63D36F-FF2B-40FF-A35C-10A18BEBD0EDQ36872129-596562C0-FCB1-4E8F-A760-3E9CA8BE683BQ37412962-D0B917B4-CE99-4DBD-867F-26F3BCAF4F9EQ37602620-8785247B-43CE-480B-8930-C62ACD6B1A03Q37735785-AF9F1C6C-AA11-4436-A740-A9ED8CFB5232Q38240136-27E1C423-8F02-4E87-95C6-9835A72E09AEQ38259329-B30EB594-AB53-4215-A807-FE88384ACCBBQ38578596-BCD22085-0441-405F-BCA6-9A2D87951160Q38620368-F1899A49-C2BC-4338-8CB3-03919301C963Q38621352-6C926236-42DC-4F0D-8773-86A235818B00Q38629654-6350A593-9F59-4865-B245-63FAC20B5F34Q38633304-114761A8-0E73-498B-A7E7-49A06740299DQ38645203-F26365A0-F963-4E67-BEC3-AAC87D972F79Q38655574-4982BF5E-C9F1-495D-B6FB-78E2149DD20FQ38740756-1379CBE9-50C9-4534-88A4-5815CB391BEDQ38751226-B55B0469-817B-4453-9081-44735F4E08A1Q38823010-D4D82A1F-6858-4361-A9FE-567F072D9DEFQ38953736-0D62EDDA-82C6-43A1-8277-6BD562530AC4Q38992596-3DC74A93-82BD-4701-808C-2A3894DE2DAFQ39386571-F8AE138C-98C6-4B8D-89C6-15701C21ABAEQ39422470-8808B39B-DA6D-4705-9ED9-F96CBDA7285CQ40238165-A2D5D0F1-C4A3-443A-82C0-A6169AC895C8Q42332533-4A11BD02-6109-425D-925D-C40F054AD9FF
P2860
Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Twice daily N-acetylcysteine 6 ...... lind placebo-controlled trial.
@en
Twice daily N-acetylcysteine 6 ...... lind placebo-controlled trial.
@nl
type
label
Twice daily N-acetylcysteine 6 ...... lind placebo-controlled trial.
@en
Twice daily N-acetylcysteine 6 ...... lind placebo-controlled trial.
@nl
prefLabel
Twice daily N-acetylcysteine 6 ...... lind placebo-controlled trial.
@en
Twice daily N-acetylcysteine 6 ...... lind placebo-controlled trial.
@nl
P2093
P1476
Twice daily N-acetylcysteine 6 ...... lind placebo-controlled trial.
@en
P2093
Bai-Song Wang
Chun-Xue Bai
Fu-Qiang Wen
Huan-Ying Wan
Jin-Ping Zheng
Luca Raiteri
Marco Sardina
Nan-Shan Zhong
P304
P356
10.1016/S2213-2600(13)70286-8
P577
2014-01-30T00:00:00Z